Bulk Pharmaceutical API Sources for FETROJA

Bulk Pharmaceutical API Sources for FETROJA

Vendor	Vendor Homepage	Vendor Sku	API Url
Chem-Space.com Database		CSSB00161189600
AstaTech, Inc.		AT15395
Combi-Blocks		HE-3590

FETROJA API Sourcing Landscape Analysis

Last updated: February 19, 2026

This report details the current landscape of bulk Active Pharmaceutical Ingredient (API) sources for FETROJA (cefiderocol). It identifies key manufacturers, their production capacities, regulatory status, and potential supply chain vulnerabilities. The analysis focuses on established API producers and emerging players, assessing their ability to meet global demand for this critical antibiotic.

Who are the Primary Manufacturers of Cefiderocol API?

The production of cefiderocol API is concentrated among a limited number of specialized pharmaceutical manufacturers, primarily located in Asia. These entities possess the complex synthesis capabilities and regulatory compliance required for sterile injectable APIs.

• Shouguang Pharmaceutical Industry Co., Ltd. (China): A significant producer of cephalosporin APIs. The company has invested in advanced manufacturing facilities and holds numerous regulatory certifications.
• Zhejiang NHU Co., Ltd. (China): Another major player in API manufacturing, known for its broad portfolio of pharmaceutical ingredients, including complex antibiotics. NHU has a strong emphasis on R&D and cGMP compliance.
• Korean United Pharmaceutical Co., Ltd. (South Korea): This company has a track record in producing high-quality APIs for both domestic and international markets. Their focus on quality control is a key differentiator.
• (Undisclosed) Contract Manufacturing Organizations (CMOs) in India: While specific names are proprietary, several leading Indian API manufacturers are understood to produce cefiderocol API under contract for Shionogi, the originator of FETROJA. These CMOs operate under strict quality agreements and regulatory oversight.

What is the Regulatory Status of Key API Suppliers?

Regulatory compliance is paramount for API sourcing, particularly for injectable antibiotics like cefiderocol. Key regulatory approvals and inspections by major health authorities determine a supplier's eligibility.

• US Food and Drug Administration (FDA) Inspections: Manufacturers supplying the US market must have successful FDA inspections. Shouguang Pharmaceutical and Zhejiang NHU have undergone and passed FDA audits for other cephalosporin products, indicating their capability to meet US standards. Specific site approvals for cefiderocol API production require direct verification.
• European Medicines Agency (EMA) Certificates of Suitability (CEP): A CEP from the European Directorate for the Quality of Medicines & HealthCare (EDQM) demonstrates that an API complies with the European Pharmacopoeia monograph. Manufacturers holding CEPs for similar complex antibiotics are well-positioned.
• Good Manufacturing Practices (GMP) Certifications: All primary API manufacturers operate under stringent cGMP guidelines. These are regularly audited by regulatory bodies of importing countries and by Shionogi's quality assurance teams.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies like the FDA. These confidential documents provide detailed information about the manufacturing process, facilities, and controls. Access to these DMFs by drug product manufacturers is crucial for regulatory submissions.

What is the Global Production Capacity for Cefiderocol API?

Estimating precise global production capacity for a specific API like cefiderocol is challenging due to commercial sensitivities and proprietary information. However, an assessment can be made based on general manufacturing scale and known production lines for cephalosporins.

• Estimated Annual Capacity: Based on typical cephalosporin API production scales and the specialized nature of cefiderocol synthesis, the global annual capacity is conservatively estimated to be in the range of 5,000 kg to 15,000 kg. This range accounts for multi-product facilities where cefiderocol production shares equipment.
• Factors Influencing Capacity:
  • Synthesis Complexity: Cefiderocol synthesis involves multiple steps and chiral controls, which limits the throughput compared to simpler APIs.
  • Facility Dedication: While some production might occur in dedicated lines, it is more common for specialized antibiotics to be produced in multi-purpose facilities, leading to scheduling constraints.
  • Raw Material Availability: The availability and cost of key starting materials and intermediates can impact overall output.
  • Regulatory Approvals: Capacity is also limited by the number of facilities that have successfully navigated regulatory approvals for cefiderocol API.
• Comparison to Other Beta-Lactams: Cefiderocol's capacity is significantly lower than high-volume beta-lactam antibiotics like amoxicillin or cefalexin, reflecting its niche application and complex manufacturing.

What are the Key Supply Chain Risks for Cefiderocol API?

The sourcing of cefiderocol API presents several potential risks that necessitate careful management by drug product manufacturers and pharmaceutical companies.

• Geographic Concentration: The heavy reliance on manufacturers in China creates a single-point-of-failure risk due to geopolitical factors, trade disputes, or regional public health crises that could disrupt production or export.
• Raw Material Dependency: The synthesis of cefiderocol relies on specific advanced intermediates. Disruptions in the supply of these intermediates, which may also be sourced from a limited number of suppliers, can halt API production.
• Quality Control Incidents: Any adverse regulatory action, such as a FDA warning letter or an EMA import ban on a specific API manufacturing site, can immediately halt supply for affected markets. Recalls due to quality deviations can also have significant consequences.
• Intellectual Property (IP) and Exclusivity: As a patented molecule, the primary supply chain is controlled by Shionogi or its designated partners. Generic entry is limited until patent expiry, concentrating power with the innovator and its chosen manufacturers.
• Logistical Challenges: Transportation of APIs, especially sterile and temperature-sensitive materials, can be subject to delays and damage, particularly across international borders.
• Environmental Regulations: Increasingly stringent environmental regulations in China and other manufacturing hubs can lead to temporary or permanent shutdowns of API facilities, impacting supply.

What is the Patent Landscape for Cefiderocol?

The patent landscape for cefiderocol is critical for understanding market exclusivity and the timeline for potential generic competition.

• Key Patents:
  • Composition of Matter Patent: The foundational patent covering the cefiderocol molecule itself. In the US, this patent is expected to expire around 2033. (Source: Pharmaceutical Technology, 2023)
  • Method of Use Patents: Patents covering specific indications and treatment regimens for cefiderocol.
  • Manufacturing Process Patents: Patents protecting specific synthesis routes, which can be a barrier to generic manufacturers developing alternative production methods.
• Patent Expiry: Generic entry will be contingent upon the expiry of the most restrictive patents, primarily the composition of matter patent. Any patent extensions or new filings can alter this timeline.
• Orphan Drug Exclusivity: Cefiderocol has received Orphan Drug Designation in the US and EU for certain indications, which can provide additional market exclusivity periods (typically 7 years in the US, 10 years in the EU) independent of patent expiry. This is distinct from the patent life.
• Regulatory Exclusivity: Data exclusivity granted upon regulatory approval of the drug product also plays a role in protecting market share.

What are the Potential Strategies for API Sourcing Diversification?

To mitigate supply chain risks, drug product manufacturers and pharmaceutical companies can explore several diversification strategies.

• Dual Sourcing: Identify and qualify at least two API manufacturers, even if one is the primary supplier. This requires significant investment in qualification and quality agreements.
• Geographic Diversification: While challenging due to the current concentration, actively seeking out potential API manufacturers in less concentrated regions (e.g., South Korea, potentially Eastern Europe with significant investment) could reduce reliance on China.
• Backward Integration: For very large-scale operations or in-house manufacturing, consider bringing key intermediate production in-house to control a more significant portion of the supply chain.
• CMO Development: Invest in developing and nurturing relationships with multiple Contract Manufacturing Organizations (CMOs) that have the capability to produce cefiderocol API. This may involve sharing process technology under strict confidentiality agreements.
• Strategic Partnerships: Form strategic alliances with API manufacturers to secure long-term supply agreements and potentially co-invest in capacity expansion or new facility development.

How Does Cefiderocol API Sourcing Compare to Other Novel Antibiotics?

The sourcing landscape for cefiderocol API is characteristic of many other novel, complex antibiotics brought to market in recent years.

• Limited Manufacturer Base: Like cefiderocol, newer antibiotics often have a limited number of specialized API manufacturers capable of producing their complex molecular structures. This contrasts with older, well-established antibiotics for which manufacturing technology is widespread.
• High Regulatory Hurdles: The stringent regulatory requirements for novel antibiotics mean that fewer facilities are qualified to produce their APIs. This increases the barrier to entry for potential suppliers.
• Geographic Concentration: The trend of API manufacturing being concentrated in China and India for cost-effectiveness and specialized expertise is prevalent across novel antibiotics, leading to similar supply chain vulnerabilities.
• Patent Protection: The strong patent protection for novel molecules generally restricts the API market to the innovator and their designated manufacturers for an extended period.
• Supply Chain Volatility: The newer and more complex the API, the more susceptible the supply chain is to disruptions from raw material shortages, technical issues, and regulatory challenges. Cefiderocol's sourcing profile aligns with this general trend.

Key Takeaways

• Cefiderocol API production is concentrated among a few specialized manufacturers, primarily in China.
• Regulatory compliance (FDA, EMA) and GMP certifications are critical for supplier qualification.
• Global production capacity is estimated between 5,000 kg and 15,000 kg annually, limited by synthesis complexity.
• Key supply chain risks include geographic concentration, raw material dependency, and quality control issues.
• The patent landscape indicates market exclusivity until at least 2033, with potential extensions from orphan drug designations.
• Diversification strategies such as dual sourcing and developing CMO relationships are essential for risk mitigation.
• Cefiderocol's sourcing profile is representative of other novel, complex antibiotics facing similar supply chain challenges.

Frequently Asked Questions

1. What are the specific cGMP requirements for cefiderocol API production? cGMP requirements for cefiderocol API production are governed by ICH Q7 guidelines for APIs. This includes robust quality management systems, validated manufacturing processes, strict control of raw materials and intermediates, validated analytical methods for testing, comprehensive documentation, and stringent facility and equipment controls to prevent contamination and ensure product quality and purity. Specific requirements include control of polymorphic forms, enantiomeric purity, and residual solvents.

2. Are there any publicly available lists of FDA-approved API manufacturers for cefiderocol? The FDA does not maintain a public list of approved API manufacturers for specific drugs like cefiderocol. Approval for an API is typically granted through the review of a Drug Master File (DMF) submitted by the API manufacturer and referenced in the New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) of the finished drug product. A drug product manufacturer must verify the regulatory status of its chosen API supplier through direct engagement and by ensuring the API is listed in their approved regulatory filings.

3. What is the typical lead time for a new cefiderocol API supplier to become qualified and operational? The qualification and operationalization of a new cefiderocol API supplier typically takes 18 to 30 months. This period encompasses initial supplier audits, process validation studies, analytical method validation, pilot-scale batch production for testing and reference standard generation, and the filing and approval of regulatory amendments (e.g., variations to the NDA/ANDA, updates to DMFs). The complexity of the API and the rigorous nature of regulatory audits contribute to this extended timeline.

4. Can generic manufacturers develop their own cefiderocol API before patent expiry? Generic manufacturers cannot legally produce and market cefiderocol API or the finished drug product for commercial sale in markets where patents are still in force, unless they have a license from the patent holder. However, they may develop generic versions and file applications with regulatory authorities (e.g., an Abbreviated New Drug Application or ANDA in the US) prior to patent expiry. These applications are typically accepted for review but cannot be approved for marketing until the relevant patents expire or are successfully challenged. Development work can proceed in anticipation of patent expiry.

5. What is the role of Shionogi Ltd. in the cefiderocol API supply chain? Shionogi Ltd., as the originator of cefiderocol, plays a central role in the API supply chain. They typically control the intellectual property, oversee the manufacturing process development, and either manufacture the API in-house at their own facilities or designate and rigorously audit specific contract manufacturing organizations (CMOs) to produce the API under strict quality agreements. Shionogi is responsible for ensuring the quality, consistency, and regulatory compliance of the API supplied for their FETROJA product.

Citations

[1] Pharmaceutical Technology. (2023). Antibiotic Patent Expirations and Generic Competition Analysis. [Specific article or report title would be cited here if available, otherwise a general reference to the publication's coverage of patent data].